Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.

Presenters:

Jyoti D. Patel, MD
Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Diwakar Davar, MD
Assistant Professor, Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/3r9BLmB

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.